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Chromosomal rearrangements are recurrent findings in human 
cancer and result in aberrant restructuring of the genome. The 
majority of known fusion genes are the consequence of recip-
rocal (balanced) translocations. However, most translocations 
described in human cancer are unbalanced, suggesting that other 
cancer genes remain to be identified. Historically, it was assumed 
that these unbalanced rearrangements affected gene function 
through the loss or gain of chromosomal material. However, 
emerging data supports direct disruption of genes located at 
or close to the unbalanced translocation breakpoints. New 
approaches are required for the identification of those gene loci 
underlying unbalanced translocations in cancer, as traditional 
methods have had limited success. This review focuses on one 
such strategy, using traditional and innovative molecular tech-
nologies to characterize breakpoint heterogeneity within a series 
of acute lymphoblastic leukemia (ALL) patients with dicentric 
chromosomes. This approach has shown that in ALL, specific 
gene loci can be targeted by heterogeneous translocation break-
points involving multiple partner chromosomes. Carcinomas 
have a high proportion of unbalanced rearrangements and rela-
tively few significant genes have been identified. The application 
of the same strategy to their analysis will lead to the discovery of 
novel cancer genes and improve our understanding of the genetic 
basis of tumorigenesis.
Introduction
In 1914, Theodor Boveri proposed that cancer developed from a 
single cell that acquired a genetic alteration.1 However, this theory 
remained unproven until several technological advances had been 
made. In the 1950s, procedures of cell culture and cytogenetic 
preparation were developed,2,3 which ultimately established that 
the normal human karyotype had a chromosome complement of 
46.4 These developments paved the way for the discovery of the 
first acquired chromosomal abnormality in human cancer; the 
presence of a small chromosome, termed the Philadelphia (Ph) 
chromosome, in patients with chronic myeloid leukemia (CML).5 
With the advent of chromosomal banding techniques in the early 
1970s,6,7 the Ph chromosome was shown to result from a balanced 
translocation, t(9;22)(q34;q11.2).8 It was nine years later that the 
molecular consequences of the translocation were identified to be 
the result of a fusion between the BCR and ABL1 genes.9,10 In 
subsequent years, chromosomal banding and molecular techniques 
have revealed many specific, recurrent chromosomal aberrations in 
a variety of tumour types, verifying the link between chromosomal 
abnormalities and cancer. More recently, the advent of molecular 
cytogenetic techniques, such as fluorescence in situ hybridiza-
tion (FISH), multiple color FISH and array-based comparative 
genomic hybridization (aCGH)11-13 have provided detailed infor-
mation which has improved our understanding of the relationship 
between changes at the chromosomal level and cancer biology. 
Particularly in leukemia, since specific chromosomal changes were 
shown to provide diagnostic information and to be associated 
with outcome; cytogenetic analysis has played a significant role 
in patient management and risk stratification for treatment. The 
discovery that aberrant tyrosine kinase signaling was the biological 
consequences of the BCR-ABL1 chimeric fusion in CML has led 
to the use of a selective tyrosine kinase inhibitor, Imatinib, in the 
treatment of this disease. This was the first example of a therapeutic 
approach specifically targeting a chromosomal rearrangement.14
It is now accepted that cancer is a genetic disease in which 
chromosomal alterations are a consistent feature, which may be 
pathogenetically significant as cancer initiating events. Chromosomal 
abnormalities are described according to the International System 
for Human Cytogenetic Nomenclature15 (Fig. 1). They can be 
sub-divided into ‘primary  abnormalities’, thought to be important 
initiating events, and ‘secondary abnormalities’, acquired during 
clonal evolution,16 and likely to play an important role in disease 
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maintenance and progression. Primary abnormalities are gener-
ally balanced rearrangements, while secondary events tend to be 
genomically unbalanced, such as monosomies, deletions, trisomies 
and duplications (Fig. 2). The majority of balanced transloca-
tions are characterized by two alternative molecular mechanisms: 
(1) genes at both breakpoints can fuse to form a hybrid, chimeric 
gene, or (2) an apparently normal gene can be upregulated 
by becoming juxtaposed to a foreign activator element on the 
partner chromosome.17 There is now overwhelming evidence that 
cancer pathogenesis is driven by such events. Firstly, the use of 
experimental animal models has shown that these chromosomal 
abnormalities are generally the initiating events of the neoplastic 
process.18 Secondly, in vitro silencing of the fusion gene transcript, 
using small non-coding RNA molecules, leads to the reversal of 
tumorigenicity, decreased cellular differentiation and prolifera-
tion.19 Thirdly, translocations are usually closely linked to specific 
tumor phenotypes.20 Finally, successful treatment is associated 
with a decrease or eradication of the clone carrying the acquired 
fusion gene.21 The increasing importance of chromosomal rear-
rangements in cancer is clearly demonstrated by the World Health 
Organization Classification of Tumours which is employing an 
increasing number of genetic changes to define disease entities.
To date, clonal chromosomal rearrangements have been found 
in all major tumour types from more than 55,000 patients (http://
cgap.nci.nih.gov/Chromosomes/Mitelman). Compared to haema-
tological malignancies, our understanding of the chromosomal 
abnormalities of solid tumors is severely limited. Technical difficul-
ties have limited chromosomal analysis of solid tumours, in which 
the chromosome morphology can be poor and genomes are often 
highly complex. These problems are reflected by the fact that solid 
tumors comprise only 27% of the total number of cases with an 
abnormal karyotype described in the literature, and that only 70 
fusion genes have been reported in solid tumours compared to 
264 in haematological malignancies.22 Among the fusion genes 
reported in solid tumours, 41 (58%) have been described in rare, 
but well studied types, such as mesenchymal and neuroectodermal 
tumours. The RET-CCDC6 fusion in thyroid carcinoma was the 
first of only a small number of fusion genes identified in epithelial 
tumour types.23 It has been shown that in every tumour type, in 
particular solid tumours, the number of recurrent fusion genes is a 
simple function of the number of cases described with an abnormal 
karyotype.24 Therefore, it is highly likely that a large number of 
genetic alterations remain unidentified. This prediction is substan-
tiated in prostate and non-small cell lung cancer, where a variety 
of fusion genes have been recently identified at high frequencies, 
including TMPRSS2-ERG, TMPRSS2-ETV1, TMPRSS2-ETV4 
and EML4-ALK.25-27
Genomic imbalances may result from simple deletion and 
duplication events. Several important cancer genes have been 
identified within such regions, but almost exclusively when the 
regions of genomic imbalance are small and contain only a few 
genes. One example is amplification of the chromosome band, 
17p21.1, containing the ERBB2 receptor tyrosine kinase, which 
occurs in approximately 30% of women with breast cancer.28 The 
consequences of genomic imbalances can be more complex, in 
which genes targeted at both copy number breakpoints can form 
a fusion sequences. For example, there are several gene fusions 
that are described in the context of genomic imbalances, such as 
NUP214-ABL1 and SIL-TAL1 in T-lineage acute lymphoblastic 
leukaemia (ALL), occurring in amplified episomes and as the result 
of a cryptic deletion, respectively.29,30 A more comprehensive list 
of genomic imbalances that result in gene fusion and deregulation 
events is shown in Table 1. However, most imbalances are large 
and contain multiple genes, often resulting from the formation 
of unbalanced chromosomal translocations, which are frequent 
in solid tumours (Fig. 2). Historically, it has been assumed that 
the consequences of unbalanced chromosomal translocations 
are loss and gain of chromosomal material and determining 
their molecular targets has been problematical. Firstly, the key 
issue has been technical, due to the unbalanced nature of the 
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Figure 1. Show an idiogram for the human normal chromosome 7. The 
46 chromosomes in a normal cell are paired and divided into autosomes, 
numbered from 1 to 22 determined by decreasing order of length and 
centromere position, and the sex chromosomes, referred to as X and Y. 
The centromeres divides the chromosomes into long (q) and short (p) arms. 
Chromosomes are arrested during metaphase and chemically modified 
(generally an enzymatic digestion followed by staining) to produce a 
specific banding pattern when viewed using a brightfield microscope. The 
bands are numbered from the centromere outwards. Analysis of the band-
ing pattern allows the identification of normal and structurally rearranged 
chromosomes.15
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partner genes scattered throughout the genome.31 In spite of these 
limitations, fusion sequences resulting from unbalanced transloca-
tions are beginning to emerge whose mechanisms of action can act 
through the formation of a transcriptionally active fusion gene, or 
by deregulation of a single gene on one chromosome (Table 1).
New approaches are required for the identification of the caus-
ative gene loci underlying unbalanced translocations in cancer, 
as traditional approaches have had limited success. This review 
focuses on one such strategy, involving traditional and innovative 
molecular techniques to define breakpoint heterogeneity in a large 
series of patients with dicentric chromosomal abnormalities.32,33
Dicentric Chromosomes in ALL: A Genetic Model of 
Unbalanced Translocations in Cancer
Examples of unbalanced translocations in which both break-
point heterogeneity and a multiplicity of partner chromosomes are 
found are the dicentric chromosomes. These abnormal chromo-
somes occur in the leukemic cells of patients with B cell precursor 
ALL (BCP ALL). They principally involve chromosomes 7, 9, 12 
and 20 in dic(7;9)(p11;p11), dic(9;12)(p11~13;p13) and dic(9;20)
(p11~13;q11), although others have been described in rare cases 
(Fig. 3). The dic(7;9) is a recurrent, but rare abnormality, with less 
than 25 cases published.34,35 It has been found as a secondary event 
in association with the translocation, t(9;22)(q34;q11) (BCR-ABL1 
fusion), suggesting that it is an important cooperating event. The 
most frequent dicentric chromosome in ALL is the dic(9;20). It is 
a subtle rearrangement which may be misinterpreted as monosomy 
20 by conventional G-banding alone,36 thus it was not reliably 
identified until FISH became available.37,38 The breakpoint 
heterogeneity exhibited at the cytogenetic level by the dic(7;9) 
and dic(9;20) was demonstrated by recent aCGH studies.39,40 
Among seven dic(9;20) and three dic(7;9) cases, aCGH showed 
no recurrent breakpoints, although clustering was observed within 
sub-bands 9p13.1-13.2, 7p11.2-p14.1 and 20q11.2.39,40 The best 
rearrangement; traditional breakpoint mapping experiments are 
less reliable when only one breakpoint is available for anal-
ysis. Secondly, one type of derivative chromosome may show 
considerable breakpoint heterogeneity between patients, so that 
recurrent involvement of genes is not identified. This may be 
further compounded by the fact that the unbalanced chromosomal 
translocations involve multiple partner genes; a situation analo-
gous to the promiscuity of genes such as MLL with more than 40 
Figure 2. Chromosomal alterations in human malignancy. These abnormalities can be sub-divided based on whether the alteration results in no change 
in chromosomal dosage (balanced) or a genomic imbalance (unbalanced). Balanced rearrangements include inversions: pericentric involves the centrom-
ere, paracentric occurs within one chromosome arm; translocation: a reciprocal exchange of chromosomal material between chromosomes. Genomic 
imbalances are categorized into gain and loss. Genomic imbalances result from numerical and structural rearrangements. Numerical alterations include 
loss (monosomy) and gain (trisomy) of entire chromosome. Structural imbalances include intra-chromosomal or extra-chromosomal amplification, cytoge-
netically visible and submicroscopic deletions, and imbalances that are the result of unbalanced translocations.
Table 1  Gene fusion events in human cancer that are 
the result of genomic imbalances
Genes Disease Genomic imbalance Reference
Chimeric fusion genes
PAX5-ETV6 B cell ALL Dicentric chromosome Cazzaniga 
   et al.42
NUP214-ABL1 T cell ALL Episomal amplification Graux et al.29
SIL-TAL1 T cell ALL Cryptic deletion Bernard et al.30
SET-NUP214 T cell ALL Cryptic deletion Van Vlierberghe 
   et al.64
MLL-CBL AML Cryptic deletion Fu et al.65
FIP1L1- Hypereosinphilic Cryptic deletion Cools 
PDGFRA syndrome  et al.66
COL1A1- Fibrosarcoma Supernumerary marker Sirvent et al.67 
PDGFB
ASPL-TFE3 Sarcoma Derivative chromosome Ladanyi et al.68
TMPRSS2-ERG Prostate Cancer Cryptic deletion Tomlins et al.25
Gene deregulation events
PAX5 B cell ALL Dicentric chromosome An et al.32
TLX3 B cell ALL Derivative chromosome Jalali et al.46
LMO2 T cell ALL Cryptic deletion Van Vlierberghe 
   et al.69
BRAF3 Astrocytomas Cryptic duplication Jones et al.70
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and aCGH, being located within both the euchromatic and 
heterochromatic regions of 9p. In spite of this heterogeneity, the 
abnormalities resulted in the deletion of a large number of genes on 
9p. These included the tumour suppressor gene, CDKN2A (Fig. 4) 
and either deletion of the entire or only part of PAX5. The latter, 
with breakpoints located within the gene, suggested that PAX5 
may be involved in the formation of chimeric fusion sequences in 
these cases including dic(7;9), dic(9;12) and dic(9;20). A FISH 
mapping study demonstrated that in the majority of dic(9;12) 
cases,  breakpoints occurred within the ETV6 gene (72%), while 
the remaining cases had deletion of the entire ETV6 locus. These 
observations conflict with the previous claims that the PAX5-ETV6 
fusion defines BCP ALL patients with the dic(9;12).43 Interestingly, 
breakpoint cloning showed that a single case had a novel break-
point within intron 1 of ETV6, which resulted in the retention 
of the entire N-terminal (SAM) domain of the predicted fusion 
protein, potentially altering the protein-protein interactions that 
are exhibited by the frequent ETV6 intron 2 breakpoint.44
Molecular studies employing molecular copy number counting 
(MCC), long distance inverse PCR and direct sequence analysis 
of those cases with a breakpoint within the PAX5 locus revealed 
fusion sequences in all dicentric sub-groups; dic(7;9), dic(9;12) 
and dic(9;20). The advantage of the MCC technique is that it 
allows the progressive delineation of unbalanced copy number 
breakpoints to within a few hundred base-pairs which narrows 
down the region of interest to facilitate rapid sequence analysis. 
It uses sub-genome quantities of DNA distributed into a 96-well 
plate, in which the frequency of PCR well positivity for any given 
characterized of the dicentric chromosomes is the dic(9;12).41 It 
has been shown to occur in association with the translocation, 
t(12;21)(p13;q22) (ETV6-RUNX1 fusion). Although breakpoint 
heterogeneity is characteristic of dic(9;12), the breakpoints cluster 
more specifically. Cazzaniga et al. showed that a novel chimeric 
transcript contained the NH2-terminal region of PAX5 and most 
of the ETV6 gene at 12p13.42 Since then it has been proposed 
that the PAX5-ETV6 fusion defines the dic(9;12).43 More recently, 
Fazio et al. reported that in such cases the PAX5-ETV6 fusion 
protein acts as an aberrant transcription factor with repressor 
function, resulting in a block in B-cell differentiation. In a PAX5-
deficient context, the presence of PAX5-ETV6 was shown not to 
replace wild-type PAX5 function, while conferring cells with a 
proliferative advantage and increased survival. Thus, these findings 
indicate that in vitro the PAX5-ETV6 fusion protein provides a 
dominant effect over wild-type PAX5, interferes with the process 
of B-cell differentiation and migration and induces resistance to 
apoptosis.44
These data on heterogeneity of breakpoints indicate that the 
establishment of an accurate and appropriate methodology for the 
identification of dicentric chromosomal target genes is required 
which could be successfully applied to gene identification in other 
leukemia and cancer types.
Variable Breakpoints Target PAX5 on Chromosome 9
A number of studies have attempted to identify the genetic 
targets of dicentric chromosomes.32,39,40 The breakpoints on 
chromosome 9 were shown to be highly heterogeneous by FISH 
Figure 3. Dicentric chromosomal abnormalities in patients with BCP ALL. (A and B) show FISH images of dic(9;20). Using whole chromosome paints and 
centromeric probes for chromosomes 9 (green) and 20 (red) the dic(9;20) is shown (with the white arrow). The complex pattern of recurrent dicentric 
chromosome in BCP ALL is shown in (C). Partial idiograms of the four chromosomes frequently involved in the formation of dicentric chromosomes are 
shown. The arrows join the partner chromosomes that are involved in each dicentric chromosome. Isodicentric chromosomes may arise from chromo-
somes 9, 12, 17, 20 and 21 (shown by the green arrows).
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with dic(9;20).33,36,40,47,48 These studies have shown considerable 
breakpoint heterogeneity of 20q (Fig. 4), with the breakpoints clus-
tering into three chromosomal regions: type I—involving ASXL1/
C20orf112; type II—centromeric to ASXL1, resulting in deletion 
of this gene; type III—distal to ASXL1. Further sequence analysis 
revealed a range of partner gene breakpoint sequences leading to 
fusions, including; PAX5(3' region)-ASXL1, ZCCHC7-FRG1B(3' 
region) and ZCCHC7-LOC1499503(3' region), identifying several 
genes that are recurrently involved at the breakpoints in patients 
with the dic(9;20). In addition to the involvement of PAX5, it 
appears that there is recurrent involvement, by deletion and fusion, 
of ASXL1 at 20q11.21 specifically in dic(9;20). ASXL1 encodes a 
protein product of 170 kDa: a mammalian homolog of Drosophila 
ASX (additional sex combs) which has been shown to act as a novel 
ligand-dependent coactivator of the retinoic acid (RA) receptor.49 
The transactivation domain (AD; amino acids 300–655) of ASXL1 
regulates transcriptional activation by interaction with the RA 
receptor (RAR).49 RA regulates cell growth by inducing cell cycle 
arrest or apoptosis.50 RA and its derivatives have been used as 
anticancer drugs in various cancers, including acute promyelocytic 
leukaemia.51 Hence, ASXL1 may act as a potential anticancer 
target in RA-resistant cancer cells.49 The study of Schoumans et 
al. supports the involvement of ASXL1 at the breakpoint of 20q 
with their cases showing a similar pattern.40 Due to the break-
point heterogeneity of 20q, in particular the presence of the type 
III breakpoint cluster, additional genes telomeric to ASXL1 may 
be targeted by these rearrangements. A recent array-based study 
primer pair is a direct reflection of the genomic copy number 
at that site.45,46 Using this approach five fusion sequences were 
identified in which PAX5 partnered the LOC392027 (7p12.1), 
SLCO1B3 (12p12, Fig. 5), ASXL1 (20q11.21), KIF3B (20q11.21) 
and C20orf112 (20q11.21) loci. Interestingly, the PAX5-ASXL1 
and PAX5-KIF3B fusion sequences were in opposing orientation, 
while the other three fusions were in the same orientation but out 
of frame, suggesting that the biological consequence of these fusion 
events was loss of PAX5 gene function. The importance of PAX5 
disruption was further supported by studies at the expression 
level. Quantitative PCR (qRT-PCR) showed deregulation of PAX5 
expression and that of several key PAX5 target genes in patients 
with dicentric chromosomes (Fig. 6). These results provided 
convincing evidence that PAX5 expression and PAX5 protein 
function were disrupted in patients with dicentric chromosomes, 
even in the absence of a PAX5 fusion gene. In addition, deletions 
and single base pair mutations were detected in the PAX5 allele 
not involved in the translocation (Fig. 6). This suggested that the 
formation of dicentric chromosomes provided leukemic poten-
tial by abrogating normal PAX5 function in these cases. Taken 
together, these data demonstrate that PAX5 is the target of dicen-
trics involving chromosome 9 as a result of different mechanisms 
targeting different chromosomes.
Putative Gene Targets on Chromosome 20
A number of cytogenetic and FISH studies have been carried 
out to identify putative gene targets on chromosome 20 in patients 
Figure 4. FISH analysis of BCP ALL patients with dicentric chromosomal abnormalities. A partial idiogram for each of the chromosomes is shown on the 
left and right for chromosomes 9 and 12, and 20 respectively. Each black filled square shows the position of a FISH probe in relation to the gene of 
interest. Each column shows an individual patient with the position and extent of the deleted region represented by vertical blue, red and orange bar/
line for patients with a dic(9;12), dic(9;20) and dic(7;9) respectively. (The rare chromosome 7 breakpoints are not shown).
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Mullighan et al. have shown that deletion, amplification, point 
mutation and structural rearrangements in genes encoding regula-
tors of B-lymphocyte development and differentiation occur in 
40% of childhood B-precursor ALL.58 The gene most frequently 
mutated in these patients was PAX5 in 32% of cases.58
In addition to its involvement in dicentric chromosomes, the 
coding sequence of PAX5 can be disrupted by several other chro-
mosomal translocations. Some of these result in the formation 
of in-frame fusion genes, listed in Table 2. Nebral et al. (2009) 
provided further support for the key role of PAX5 in ALL in a 
comprehensive FISH analysis of 446 ALL patients.53 Using a 
break-apart FISH probe for PAX5, they showed that PAX5 rear-
rangements occur at an incidence of approximately 2.5%. They 
also showed considerable signal pattern heterogeneity, including 
split signals and 3' and 5' deletions. Among the 10 cases that 
identified three dic(9;20) cases with 
deletion of 9p and 20q, the molecular 
consequence of which was a recur-
rent PAX5-C20ORF112 fusion, that 
specifically repressed the transcriptional 
activity of PAX5 in a dominant-nega-
tive fashion.52 Other studies have 
confirmed the recurrent nature of the 
PAX5-C20ORF112.32,53 Other genes 
within the common region of deletion 
on 20q include DIDO at 20q13.33 
and L3MBTL at 20q13.12. DIDO 
(death inducer-obliterator) is upregu-
lated by apoptotic signals and encodes 
a cytoplasmic protein that translocates 
to the nucleus upon apoptotic signal 
activation. In myeloma, DIDO has been 
proposed to act as a tumour suppressor 
gene.54 L3MBTL (lethal(3) malignant 
brain tumour-like), an imprinting gene, 
is abnormally expressed in myeloma 
cells.55,56 Although ASXL1 has been 
implicated in this study to be important 
in ALL with dic(9;20), the loss of other 
genes, such as DIDO1 and L3MBTL, 
cannot be ruled out as important addi-
tional events. Future studies should 
focus on the expression of genes on 20q, 
including ASXL1, to provide further 
insight into their role in dicentric chro-
mosomal rearrangements in BCP ALL. 
Investigations into the functional conse-
quences of these genetic events may 
implicate them as playing a key role 
in the initiation or maintenance of the 
leukemic phenotype.
Discussion
The targeting of the PAX5 gene by 
dicentric chromosomal rearrangements 
has indicated that specific gene loci may be the target of hetero-
geneous breakpoints in human cancer, acting through a variety of 
mechanisms. It is now clear that PAX5 represents a key genetic 
target in the pathogenesis of BCP ALL. PAX5 is a transcription 
factor that encodes the B-cell specific activator protein, BSAP; 
a key regulator of B-cell development. In hematopoietic cells, 
PAX5 is expressed in the B-lymphoid lineage and is required for 
maturation beyond the pro-B-cell stage. Studies using conditional 
knockdown approaches have shown that PAX5 fulfils a dual role 
during B-cell commitment by repressing B-lineage inappropriate 
genes and simultaneously activating B-cell-specific genes. The 
PAX5 gene was first identified in lymphoma, as a consequence 
of its involvement in the balanced chromosomal translocation, 
t(9;14)(p13;q32).57 This translocation drives overexpression of 
PAX5 by juxtaposition with the potent enhancer of IGH@. 
Figure 5. Representative MCC and sequencing analysis of PAX5 disruption in a dic(9;12) patient. To 
the left are partial idiograms of chromosome 9 and 12 demonstrating the structure of the dic(9;12). 
Molecular analysis of the dicentric breakpoint is shown to the right. The x and y axes of the final round 
of MCC analysis (top) show the genomic position and degree of copy number change respectively. The 
size and position of the copy number change is shown by the dashed box. The fusion sequence (middle) 
is shown between normal sequence for chromosome 9 and 12, where the later is underlined. The sche-
matic of the PAX5 genomic breakpoints and partner gene (bottom) shows the exon structure of PAX5 and 
SLCO1B3 as white and grey boxes respectively. The gene orientation is shown by the horizontal arrows. 
Below the genomic schematic is the corresponding predicted protein structure and domains. PD: paired, 
oATP: organic anion transporter polypeptide, KAZAL-ALC21: azal-type serine protease inhibitor.
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displayed a FISH signal pattern characteristic of a PAX5 rear-
rangement, they identified a further five fusion partners to PAX5: 
HIPK1, POM121, JAK2, DACH1 and BRD1. Several studies have 
investigated the functional roles of these PAX5 fusion genes and 
shown similarities regardless of the PAX5 fusion partner. One such 
example is fusion of the paired box domain of the PAX5 gene to 
the elastin (ELN) gene.59 The function of PAX5-ELN is analogous 
to several other reported PAX5 fusion genes, where the fusion gene 
truncated PAX5 and disrupted wild-type PAX5 function reflected 
by deregulated expression of PAX5 target genes.44,52,58,59 The 
genes at the breakpoints of dicentric chromosomes, as described 
above, were either out-of-frame or in opposing orientations. This 
suggested that the biological consequence of these fusion sequences 
is loss of PAX5 function, rather that the gain of functional elements 
as a consequence of the fusion event, providing further support for 
PAX5 as playing a key role in the pathogenesis of BCP ALL.
It is clear that the prominent target genes include PAX5 
and ETV6, either by the formation of fusion sequences or by 
deletion. Chromosome 20 target genes may include ASXL1 or 
C20ORF112; fusions involving the latter have been reported by 
several groups.32,52,53 Further study is required to confirm the 
importance of these genes as the breakpoints on 20q are particu-
larly heterogeneous. However, if the recurrent involvement of 
Figure 6. Quantitative PCR analysis of expression, copy number and sequence analysis of BCP ALL patients with dicentric chromosomes. (A) Quantitative 
RT-PCR analysis of PAX5 and PAX5 target gene expression. The patient subgroup and fold change in expression are shown in the x and y axes, respec-
tively. Patients with a dicentric chromosome resulting in either fusion or deletion of PAX5 [dic (fused/del)] and with a high hyperdiploid karyotype [HeH 
(retained)]. (C) Quantitative genomic PCR for exon 6 of PAX5. Based on a series of control patients (n = 180) with two normal copies of PAX5 a minimal 
ratio for a normal copy number was defined and is shown by the horizontal dashed line. Each patient is shown as a vertical bar on the x axis, where 
N1-N8 (light blue) are patients with two copies of PAX5, 12-4443 and 20-10061, have homozygous, and 20-4887 has heterozygous loss of PAX5. 
(C) PAX5 mutation analysis a patients with a dicentric chromosomes. The DHPLC traces for a normal and patient 20-4887, where the x and y axes 
show retention time and spectrophotometrical detection at 253 nM, respectively (above). Sequence traces for patient 20-4887 contained a DelG1450 
frame-shift mutation in exon 8, which translates to a truncated protein composed of the original 334AA of PAX5 then a sequence of 19AA followed by 
a premature stop (below).
Table 2  Reported PAX5 fusion sequences in  
haematological malignancy
Disease Genetic consequences Reference
Lymphoma PAX5-IGH@ Busslinger et al.57
B ALL PAX5-ETV6 Cazzaniga et al.42, Strehl et al.43
B ALL PAX5-ELN Bousquet et al.59
B ALL PAX5-FOXP1 Mullighan et al.58
B ALL PAX5-ZNF521 Mullighan et al.58
B ALL PAX5-PML Nebral et al.71
B ALL PAX5-C20ORF112 An et al.32, Kawamata et al.52
B ALL PAX5-AUTS2 Kawamata et al.52
BCP ALL PAX5-JAK2 Nebral et al.53
BCP ALL PAX5-POM121 Nebral et al.53
BCP ALL PAX5-HIPK1 Nebral et al.53
BCP ALL PAX5-DACH1 Nebral et al.53
BCP ALL PAX5-LOC392027 An et al.32
BCP ALL PAX5-SLCO1B3 An et al.32
BCP ALL PAX5-ASXL1 An et al.32
BCP ALL PAX5-KIF3B An et al.32
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mutations and epigenetic changes. Analysis of gene or protein 
expression will provide evidence that a target gene is aberrantly 
expressed in the sample cohort. A schematic of the approach is 
shown in Figure 7.
In conclusion, there is now an efficient strategy for the identifi-
cation of cancer genes, in which specific gene loci can be targeted 
by heterogeneous translocation breakpoints involving multiple 
partner chromosomes. This is supported by the identification of 
PAX5 as a key genetic target of dicentric chromosomes in patients 
with ALL. In the absence of a dicentric chromosome, PAX5 is also 
targeted by interstitial deletions and copy number neutral LOH 
events,58,61 further supporting the importance of investigating the 
underlying molecular basis of unbalanced translocations. High-
throughput sequencing strategies are emerging which will enhance 
the discovery of aberrant genes in cancer cells.62,63 However, the 
simple approach described here offers cost-effective and accessible 
method for the identification of genes in other cancer types, in 
which unbalanced rearrangements are prevalent and relatively 
few genes have been identified. A large number of novel cancer-
related genes are likely to emerge, expanding our understanding of 
carcinogenesis and ultimately leading to improved management of 
patients with cancer.
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